The risk of UK medicine shortages is rising sharply, with experts warning Britain could face supply disruptions within weeks if the Iran conflict continues, potentially affecting everything from basic painkillers to advanced cancer treatments.
Industry specialists say the escalating war in the Middle East is already disrupting global supply chains for essential pharmaceutical ingredients, transport routes and raw materials—raising fears of shortages and price increases across the UK healthcare system.
Supply chain disruption threatens UK medicine availability
The growing concern over UK medicine shortages stems from the disruption of critical global supply routes, particularly through the Strait of Hormuz, a key shipping corridor for energy and industrial materials.
Experts say the conflict has created a “perfect storm” affecting the pharmaceutical sector, as rising geopolitical tensions intersect with already fragile global supply chains.
India, often described as the “pharmacy of the world”, produces a significant share of generic medicines and active pharmaceutical ingredients (APIs) used globally. However, exporting these products has become increasingly difficult due to transport disruptions and regional instability.
At the same time, closures and reduced operations at major Middle Eastern airports have forced pharmaceutical companies to reroute shipments, adding delays and increasing costs.
Drug shortages could emerge within weeks
Industry leaders warn that UK medicine shortages could become visible within a matter of weeks if current conditions persist.
Medical distributors typically maintain between six and eight weeks of stock, while suppliers to hospitals are required to hold around eight weeks’ supply. Once these buffers are depleted, shortages could begin to affect patients directly.
Generic medicines—accounting for around 85% of drugs used by the NHS—are particularly vulnerable due to their low profit margins and reliance on complex international supply chains.
Experts caution that while the UK is not yet in a full-blown crisis, the situation is “serious” and could deteriorate rapidly if disruptions continue.
Rising transport costs add pressure on NHS supply
The conflict has significantly increased the cost of transporting medicines, especially via air freight.
One in five NHS medicines is transported by air, but the war has caused air cargo capacity to fall sharply, with flight disruptions across key Middle Eastern routes.
Air freight costs have already doubled, forcing manufacturers to absorb rising expenses—at least temporarily. However, sustained increases could make some medicines financially unviable to supply.
Meanwhile, shipping routes have also been impacted. With the Strait of Hormuz effectively restricted, some cargo is being rerouted around the Cape of Good Hope, adding up to two weeks to delivery times and significantly increasing fuel costs.
Critical medicines most at risk
Not all medicines face the same level of risk, but certain categories are particularly vulnerable.
High-value and time-sensitive treatments—including cancer therapies, biologics, gene therapies and drugs used in clinical trials—often require rapid air transport and controlled conditions.
Delays in delivery could affect patient outcomes, particularly for those requiring urgent or ongoing treatment.
More stable generic drugs can be transported by sea, but longer transit times increase the risk of supply gaps if demand rises suddenly.
Prices expected to rise if disruption continues
Experts warn that UK medicine shortages could be accompanied by price increases, particularly for drugs supplied outside long-term NHS contracts.
While hospital supply agreements often fix prices, medicines supplied through pharmacies and GP practices may see cost increases passed on more quickly.
If the conflict persists, analysts expect price rises to remain modest initially, but the longer-term impact could be more significant depending on energy costs and supply stability.
Raw material shortages compound the crisis
Beyond logistics, the war is also affecting the availability and cost of key raw materials used in pharmaceutical production.
Rising oil and gas prices are increasing the cost of petrochemical products such as methanol and ethylene, which are essential for manufacturing APIs and medical supplies.
These materials are also used in producing syringes, vials, tubing and protective equipment, meaning the impact extends beyond medicines themselves.
The broader effect is a ripple across the healthcare supply chain, increasing production costs and putting additional strain on manufacturers.
Global dependence on complex pharma supply chains
The UK relies on a highly interconnected global pharmaceutical network, with around half of its medicines produced domestically, while a significant share is imported from India and the European Union.
India alone supplies around 60% of generic medicines globally and plays a crucial role in meeting demand in the UK and the US.
Previous disruptions—such as during the Covid-19 pandemic—highlighted the vulnerability of these supply chains, with shortages of basic drugs like paracetamol seen across multiple countries.
The current situation reflects similar risks, but with added geopolitical complexity.
Wider economic impact on healthcare systems
The threat of UK medicine shortages comes at a time when healthcare systems are already under pressure from rising costs and post-pandemic recovery challenges.
Higher drug prices could increase the financial burden on the NHS, which operates within tight budget constraints.
Ultimately, analysts warn that the cost of disruption will likely be shared between governments, healthcare providers and patients, either through higher taxes, increased healthcare spending or rising out-of-pocket costs.
Uncertainty hinges on duration of conflict
The trajectory of UK medicine shortages will largely depend on how long the Iran conflict continues and whether key shipping routes can be stabilised.
If the disruption is short-lived, supply chains may recover without major consequences. However, a prolonged conflict could trigger sustained shortages and higher costs across the healthcare system.
For now, experts say vigilance is essential, with governments and industry closely monitoring stock levels and exploring contingency measures to protect medicine supplies.